Overview

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

Status:
Recruiting
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether psilocybin, a hallucinogenic drug, is effective in reducing depressive symptoms and amount of drinking in patients with co-occurring Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Treatments:
N,N-Dimethyltryptamine
Psilocybin